Formulations comprising compounds obtainable from a neem extract and/or biomass and at least one water-soluble organosilicone surfactant, and methods of making and using such formulations are provided.

A steam therapy equipment including a vessel for heating a mixture of water and organic materials, a compressor to inject pressurized air into the vessel producing pressurized steam. The pressurized steam is conducted into the equipment via one or more valves. The therapy equipment is formed from at least one panel and may include a supporting frame. The therapy equipment includes a temperature sensor to measure the temperature inside the therapy equipment when pressurized steam is admitted via the valves. A patient enters the equipment and is exposed to the pressurized steam, causing dilation of the skin pores of the patient, whereby toxins are removed from the patient. One or more applicators may conduct pressurized steam to specific portions of the body of the patient. The patient may be provided with a portion of the mixture to consume as part of the steam therapy treatment.

A steam therapy equipment including a vessel for heating a mixture of water and organic materials, a compressor to inject pressurized air into the vessel producing pressurized steam. The pressurized steam is conducted into the equipment via one or more valves. The therapy equipment is formed from at least one panel and may include a supporting frame. The therapy equipment includes a temperature sensor to measure the temperature inside the therapy equipment when pressurized steam is admitted via the valves. A patient enters the equipment and is exposed to the pressurized steam, causing dilation of the skin pores of the patient, whereby toxins are removed from the patient. One or more applicators may conduct pressurized steam to specific portions of the body of the patient. The patient may be provided with a portion of the mixture to consume as part of the steam therapy treatment.

A steam therapy equipment including a vessel for heating a mixture of water and organic materials, a compressor to inject pressurized air into the vessel producing pressurized steam. The pressurized steam is conducted into the equipment via one or more valves. The therapy equipment is formed from at least one panel and may include a supporting frame. The therapy equipment includes a temperature sensor to measure the temperature inside the therapy equipment when pressurized steam is admitted via the valves. A patient enters the equipment and is exposed to the pressurized steam, causing dilation of the skin pores of the patient, whereby toxins are removed from the patient. One or more applicators may conduct pressurized steam to specific portions of the body of the patient. The patient may be provided with a portion of the mixture to consume as part of the steam therapy treatment.

Antimicrobial compositions include a therapeutically effective amount of neem oil, extract of the plant Hypericum spp., polyunsaturated fatty acids (PUFAs), carrageenans, and/or chlorhexidine; and (optionally) in combination with one or more pharmaceutically acceptable carriers, additives, and/or diluents. The antimicrobial compositions are effective in treating or preventing upper respiratory tract infections, preferably upper respiratory tract infections caused by human Coronaviruses and are included within methods of treating or preventing infection of the upper respiratory tract of humans by a microbial pathogen.

Antimicrobial compositions include a therapeutically effective amount of neem oil, extract of the plant Hypericum spp., polyunsaturated fatty acids (PUFAs), carrageenans, and/or chlorhexidine; and (optionally) in combination with one or more pharmaceutically acceptable carriers, additives, and/or diluents. The antimicrobial compositions are effective in treating or preventing upper respiratory tract infections, preferably upper respiratory tract infections caused by human Coronaviruses and are included within methods of treating or preventing infection of the upper respiratory tract of humans by a microbial pathogen.

Antimicrobial compositions include a therapeutically effective amount of neem oil, extract of the plant Hypericum spp., polyunsaturated fatty acids (PUFAs), carrageenans, and/or chlorhexidine; and (optionally) in combination with one or more pharmaceutically acceptable carriers, additives, and/or diluents. The antimicrobial compositions are effective in treating or preventing upper respiratory tract infections, preferably upper respiratory tract infections caused by human Coronaviruses and are included within methods of treating or preventing infection of the upper respiratory tract of humans by a microbial pathogen.

Provided is a device suitable for direct topical administration of a pharmaceutical composition comprising at least one active component selected from the group consisting of cannabinoids, terpenes, flavonoids, CB1 receptor agonists, CB2 receptor agonists and combinations thereof to a region of the oral cavity of a subject and methods of use thereof. The device comprises a solid substrate having at least a portion configured and dimensioned to be contacted with the region of the oral cavity of the subject; and an amount of the pharmaceutical composition associated with at least a portion of the solid substrate, wherein the amount of pharmaceutical composition is at least partially releasable from the portion of solid substrate.

Provided is a device suitable for direct topical administration of a pharmaceutical composition comprising at least one active component selected from the group consisting of cannabinoids, terpenes, flavonoids, CB1 receptor agonists, CB2 receptor agonists and combinations thereof to a region of the oral cavity of a subject and methods of use thereof. The device comprises a solid substrate having at least a portion configured and dimensioned to be contacted with the region of the oral cavity of the subject; and an amount of the pharmaceutical composition associated with at least a portion of the solid substrate, wherein the amount of pharmaceutical composition is at least partially releasable from the portion of solid substrate.

The present invention relates to the novel formulation for sustained or delayed release of rohitukine-rich Dysoxylum binectariferum extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract/fraction of rohitukine-rich Dysoxylum binectariferum with polymers has resulted in a sustained release of the extract or fraction over a period of 16-24 hrs. The said formulations are useful in the treatment of inflammatory diseases.